Protozoa are unicellular, non-phototrophic, eukaryotic microorganisms lacking cell walls. This group comprises over 65,000 species. Most protozoa cause a number of diseases in animals and humans. In the cyst stage of the life cycle, protozoa are most dormant and resistant to environmental stress factors. Cysts are often the mode of infection in disease causing protozoa. These infectious agents are usually transmitted through fecal-oral route. The major disease-causing protozoans include Plasmodium spp., Trypanosoma spp., and Leishmania spp. Diseases caused by these protozoans lead to significant mortality, morbidity, and economy losses in developing countries. Protozoal infections arise due to poor sanitary conditions, improper hygiene, and lack of vector control methods in tropical and sub-tropical countries. Antiprotozoal drugs are therefore used to combat these diseases. Antiprotozoal drugs kill or inhibit the reproductive ability of a protozoa, preventing further infections.
Major diseases caused by protozoa include amebiasis, malaria, leishmaniasis, trypanosomiasis, toxoplasmosis, and giardiasis. Amebiasis is a gastrointestinal tract disease, caused by Entamoeba histolytica, which is an anaerobic parasitic protozoan. 50 million people worldwide are infected with Entamoeba histolytica. Diarrhea and dysentery are the most common signs and symptoms of this infection. Malaria is transmitted through the bite of a female Anopheles mosquito. Patients show symptoms of fever and chills. Plasmodium falciparum, vivax, malariae, and ovale are the causative agents of malaria. The disease is endemic in various countries.
Leishmaniasis, trypanosomiasis, toxoplasmosis, and giardiasis are the most common protozoan infections leading to a number of deaths worldwide. Demand for antiprotozoal drugs is high as there are no vaccines available for the treatment of these diseases and therapy depends on antiprotozoal drugs. Increasing demand for new antiprotozoal drugs, owing to the problems such as poor efficacy, unsuitable pharmacokinetic properties, and drug resistance of preexisting drugs. Moreover, rising population, poverty, poor hygiene, sanitary conditions in underdeveloped and developing countries, and increasing awareness about these diseases are the major drivers of the antiprotozoal drugs market. However, high cost and inadequate pharmaceutical research restrain the market.
In terms of causative agent, the antiprotozoal drugs market has been segmented into antimalarial drugs, amebicides, trichomonacides, antigiardial, leishmaniacides, trypanocides, and toxoplasmocides. Amebicides comprise antiprotozoal agents such as arsenicals, quinoline derivatives, and drugs from natural source, emetine, hydroxyquinolone, diloxanide furate, paramomycin3, carbarsone, nitroimidazole derivatives, and chloroquine. Anti-malarial drugs consists of 8-aminoqinoline, cinchona alkaloids, 4-amino quinines, 9-acridine, sulfone, and biguanides. Trichomonacides comprise metronidazole. Antigiardial consists of metronidazole. Leishmaniacides consists of sodium stibogluconate and pentamidine. Trypanocides class of drugs comprise suramin and pentamidine, while toxoplasmocides consist of pyrimethamine along with sulfadiazine. The antiprotozoal drugs market has also been segmented based on mode of action and type of treatment. In terms of end-user, the antiprotozoal drugs market has been segmented into hospitals, private clinics, pharmacies, non-governmental organizations, research institutes, and e-commerce. The pipeline for new antiprotozoal drugs is projected to boost the growth of the global antiprotozoal drugs market.
Based on region, the global antiprotozoal drugs market has been segmented into North America, Latin America, Asia Pacific, Africa, Western Europe, and Eastern Europe. However, the market is divided according to the type of infection and its prevalence in each region. For instance, the global market for antimalarial, leishmaniacides, and amebicide drugs is concentrated in developing countries in Asia Pacific and Africa. Rapid research & development activities by pharmaceutical companies can lead to introduction of new scientific technology, methods, and treatments to cure these diseases. This, in turn, is anticipated to drive demand for antiprotozoal infection drugs during the forecast period.
Key players in the global antiprotozoal drugs market include Enzon Pharmaceuticals (Abelcet), Paladin Therapeutics, Inc., Sequus Pharmaceuticals, Lifecare Innovation, Sanofi, Pfizer, Inc., Ranbaxy Laboratories, GlaxoSmithKline plc, Novartis AG, Ipca Laboratories Ltd., Merck KGaA, and F. Hoffmann La-Roche Ltd.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.